Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 26, 2013
Karyopharm Therapeutics Announces 15 Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models at the American Association of Cancer Research (AACR)...
-
Feb 5, 2013
Karyopharm Therapeutics Announces Ken Weg & Barry Greene Join Board of Directors; Dr. Sharon Shacham Named President of Research & DevelopmentNatick, Mass. February 5th 2013 Karyopharm...
-
Jan 17, 2013
Karyopharm Therapeutics Initiates Treatment of Patients with Acute Myeloid Leukemia (AML) in Phase 1 Trial with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE)Natick, Mass....
-
Dec 4, 2012
Karyopharm Therapeutics Initiates a Phase IIb Efficacy Study with its Novel, Oral Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Dogs with Non-Hodgkin Lymphomas (NHL)Natick, Mass....
-
Nov 13, 2012
Karyopharm Therapeutics Announces Eight Presentations on Selective Inhibitors of Nuclear Export (SINE) for Hematologic Malignancies at the American Society of Hematology (ASH) MeetingNatick, Mass....
-
Nov 12, 2012Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
Natick, Mass. November 12, 2012 Karyopharm Therapeutics Inc., leading the new field of nuclear transport modulators, announces an oral presentation on the use of its SINE CRM1 antagonists for the...
-
Oct 31, 2012
Karyopharm Therapeutics Announces Multiple Publications on Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in CancerNatick, Mass. October 31st, 2012 Karyopharm Therapeutics Inc.,...
-
Oct 31, 2012
Karyopharm Therapeutics Announces Multiple Publications on Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in CancerNatick, Mass. October 31st, 2012 Karyopharm Therapeutics Inc.,...
-
Jul 25, 2012
Karyopharm Therapeutics Initiates Two Phase 1 Trials with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE), in Patients with Advanced CancersNatick, Mass. July 25, 2012...
-
May 25, 2012
Karyopharm Therapeutics Announces Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid Tumor Models at the American Society of Clinical Oncology (ASCO) MeetingNatick, Mass. May...